Stock Research Monitor: GERN, GBT, and GLYC

LONDON, UK / ACCESSWIRE / June 14, 2018/ If you want a free Stock Review on GILD sign up now at www.wallstequities.com/registration. On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Geron

On Wednesday, shares in Menlo Park, California-based Geron Corp. recorded a trading volume of 3.10 million shares. The stock ended at $3.82, rising 2.41% from the last trading session. The Company's shares have gained 10.09% in the last month, 21.66% over the previous three months, and 43.61% in the last twelve months. The stock is trading above its 200-day moving average by 40.98%. Furthermore, shares of Geron, which operates as a biopharmaceutical company, have a Relative Strength Index (RSI) of 47.16. Get the full research report on GERN for free by clicking below at:

www.wallstequities.com/registration/?symbol=GERN


Gilead Sciences

Foster City, California headquartered Gilead Sciences Inc.'s stock finished yesterday's session 0.54% lower at $71.29. A total volume of 5.00 million shares was traded. The Company's shares have gained 9.42% in the last twelve months. The stock is trading above its 50-day moving average by 1.02%. Furthermore, shares of Gilead Sciences, which discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the US, Europe, and internationally, have an RSI of 58.63. Today's complimentary research report on GILD is accessible at:


www.wallstequities.com/registration/?symbol=GILD


Global Blood Therapeutics

At the close of trading on Wednesday, shares in South San Francisco, California headquartered Global Blood Therapeutics Inc. saw a rise of 0.21%, ending the day at $47.55. The stock recorded a trading volume of 685,280 shares. The Company's shares have advanced 57.97% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.89% and 7.85%, respectively. Moreover, shares of the Company, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 50.67. Register now for your free research document on GBT at:

www.wallstequities.com/registration/?symbol=GBT


GlycoMimetics

Rockville, Maryland headquartered GlycoMimetics Inc.'s shares ended the day 2.51% lower at $17.49 with a total trading volume of 521,153 shares. The stock has gained 46.85% over the last twelve months. The Company's shares are trading above their 200-day moving average by 5.55%. Additionally, shares of GlycoMimetics, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the US, have an RSI of 44.49. Click on the link below and see our free report GLYC at:

www.wallstequities.com/registration/?symbol=GLYC

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you?re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities